Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2024

06-01-2024 | Obesity | Original Article

Obesity Is Associated with Altered Rectal Sensitivity in Chronic Constipation

Authors: Nayna A. Lodhia, Brent Hiramoto, Laura Horton, Alison H. Goldin, Christopher C. Thompson, Walter W. Chan

Published in: Digestive Diseases and Sciences | Issue 3/2024

Login to get access

Abstract

Background

Defecation dysfunction may contribute to chronic constipation (CC), but the impact of obesity on anorectal physiology in CC remains unclear. We aimed to evaluate the relationship between obesity and anorectal function on physiologic testing in patients presenting with CC.

Methods

This was a retrospective cohort study of consecutive adults who underwent high resolution anorectal manometry (HRAM) at a tertiary center for CC. Patient demographics, clinical history, surgical/obstetric history, medications, and HRAM results were reviewed. Patients were classified into obese (BMI > 30 kg/m2) vs non-obese (BMI < 30 kg/m2) groups at the time of HRAM. Fisher-exact/student t-test for univariate analyses and general linear regression for multivariable analysis were performed.

Results

383 adults (mean 50.3 years; 85.8% female) with CC were included. On HRAM, patients with obesity had lower anal sphincter resting tone (37.3 vs 48.5 mmHg, p = 0.005) and maximum squeeze pressure (104.8 mmHg vs 120.0 mmHg, p = 0.043). No significant differences in dyssynergia (61% vs 53%, p = 0.294) and failed balloon expulsion (18% vs 25%, p = 0.381) were found between obese and non-obese groups. On balloon distention testing, the maximum tolerated (163.5 vs 147.6 mL, p = 0.042) and urge sensation (113.9 vs 103.7 mL, p = 0.048) volumes were significantly increased among patients with obesity. After adjusting for potential confounders, obesity remained independently associated with increased maximum tolerated volume (β-coefficient 13.7, p = 0.049).

Conclusion

Obesity was independently associated with altered rectal sensitivity among patients with CC. Altered rectal sensation may play an important role in CC among patients with obesity. Anorectal physiology testing should be considered to understand the pathophysiology and guide management.
Literature
7.
go back to reference Burgell RE, Lelic D, Carrington EV, et al. Assessment of rectal afferent neuronal function and brain activity in patients with constipation and rectal hyposensitivity. Neurogastroenterol Motil. Mar 2013;25:260–7, e167–8. https://doi.org/10.1111/nmo.12047 Burgell RE, Lelic D, Carrington EV, et al. Assessment of rectal afferent neuronal function and brain activity in patients with constipation and rectal hyposensitivity. Neurogastroenterol Motil. Mar 2013;25:260–7, e167–8. https://​doi.​org/​10.​1111/​nmo.​12047
27.
go back to reference Brochard C, Vénara A, Bodère A, Ropert A, Bouguen G, Siproudhis L. Pathophysiology of fecal incontinence in obese patients: A prospective case-matched study of 201 patients. Neurogastroenterol Motil. Aug 2017;29(8)https://doi.org/10.1111/nmo.13051 Brochard C, Vénara A, Bodère A, Ropert A, Bouguen G, Siproudhis L. Pathophysiology of fecal incontinence in obese patients: A prospective case-matched study of 201 patients. Neurogastroenterol Motil. Aug 2017;29(8)https://​doi.​org/​10.​1111/​nmo.​13051
Metadata
Title
Obesity Is Associated with Altered Rectal Sensitivity in Chronic Constipation
Authors
Nayna A. Lodhia
Brent Hiramoto
Laura Horton
Alison H. Goldin
Christopher C. Thompson
Walter W. Chan
Publication date
06-01-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-08246-z

Other articles of this Issue 3/2024

Digestive Diseases and Sciences 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine